🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shenyang Sunshine Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shenyang Sunshine Pharmaceutical as lead sponsor. Synced 26 Sep 2026
17Current trials
11Recruiting now
6Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shenyang Sunshine Pharmaceutical is the lead sponsor of 17 current clinical trials in our China register. 11 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are SSGJ-612, SSGJ-705 and Bevacizumab. The most-studied condition is Healthy.

ClinicalTrials.gov trials by status

  • Recruiting1165%
  • Not yet open529%
  • By invitation16%

Trials by phase

  • Phase 1953%
  • Phase 2635%
  • Phase 1/216%
  • Phase 316%
01

Clinical trials sponsored by Shenyang Sunshine Pharmaceutical

17 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
NCT07008703 · ClinicalTrials.gov ↗ · Cancer Pain
Phase 1/2 Recruiting 2024-03 China
SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors
NCT07022002 · ClinicalTrials.gov ↗ · Locally Advanced, Recurrent or Metastatic Malignancies
Drug: SSGJ-705
Phase 2 Recruiting 2025-07 China
Phase I Study of HBT-708 for Patients With Advanced Solid Tumors
NCT06993870 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Phase 1 Recruiting 2025-06 China
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
NCT06629376 · ClinicalTrials.gov ↗ · Gout, Hyperuricemia
Phase 1 Recruiting 2023-11 China
SSGJ-707 in Advanced Non-Small Cell Lung Cancer
NCT06980272 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer
Phase 3 Recruiting 2025-06 China
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
NCT07038005 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors
Phase 1 Recruiting 2025-07 China
SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
NCT07646626 · ClinicalTrials.gov ↗ · Locally Advanced (Unresectable) or Metastatic Solid Tumors
Phase 2 Recruiting 2026-07 China
A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors
NCT07032298 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors
Drug: SSGJ-612
Phase 1 Recruiting 2025-07 China
Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects
NCT07058779 · ClinicalTrials.gov ↗ · Safety Issues
Phase 1 Recruiting 2025-08 China
A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors
NCT06944444 · ClinicalTrials.gov ↗ · Malignant Tumors
Phase 1 Recruiting 2025-04 China
A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer(NSCLC) Patients
NCT07171606 · ClinicalTrials.gov ↗ · First-line Advanced NSCLC Patients
Phase 2 Recruiting 2025-10 China
A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants
NCT07606976 · ClinicalTrials.gov ↗ · Healthy
Phase 1 Not yet open 2026-06 China
Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia
NCT07007936 · ClinicalTrials.gov ↗ · Postoperative Anemia, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Phase 2 Not yet open 2025-07 China
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion
NCT07487545 · ClinicalTrials.gov ↗ · Healthy
Phase 1 Not yet open 2026-03 China
A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer
NCT07757230 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer
Drug: SSGJ-612
Phase 2 Not yet open 2026-09 China
A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
NCT07233850 · ClinicalTrials.gov ↗ · Gastric/Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Phase 2 Not yet open 2025-11 China
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection in Healthy Chinese Subjects
NCT07057726 · ClinicalTrials.gov ↗ · Safety and Tolerability in Healthy Volunteers
Phase 1 By invitation 2024-10 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shenyang Sunshine Pharmaceutical trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shenyang Sunshine Pharmaceutical trials

21 conditions
Healthy2Advanced Malignant Tumors2Cancer Pain1Locally Advanced, Recurrent or Metastatic Malignancies1Advanced Solid Tumors1Gout1Hyperuricemia1Advanced Non-Small Cell Lung Cancer1Postoperative Anemia1Arthroplasty, Replacement, Hip1Arthroplasty, Replacement, Knee1Safety and Tolerability in Healthy Volunteers1Metastatic Breast Cancer1Locally Advanced (Unresectable) or Metastatic Solid Tumors1Gastric/Gastroesophageal Junction Adenocarcinoma1Metastatic Colorectal Cancer (CRC)1Pancreatic Ductal Adenocarcinoma (PDAC)1Oesophageal Cancer1Safety Issues1Malignant Tumors1First-line Advanced NSCLC Patients1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1711

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Healthy

SponsorTrials
Eli Lilly and Company15
Merck Sharp & Dohme14
University of Electronic Science and Technology of China10
Olly, PBC5
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences4
Boehringer Ingelheim3
dōTERRA International3
Qualia Life Sciences2
Clinical Nutrition Research Center, Illinois Institute of Technology2
Keymed Biosciences2

Sponsors with the most current trials registered for this condition.

06

Questions about Shenyang Sunshine Pharmaceutical trials

How many clinical trials does Shenyang Sunshine Pharmaceutical sponsor?

Shenyang Sunshine Pharmaceutical is the lead sponsor of 17 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shenyang Sunshine Pharmaceutical trials recruiting?

Yes. 11 of its 17 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shenyang Sunshine Pharmaceutical testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are SSGJ-612 (3), SSGJ-705 (2), Bevacizumab (1), PF-08634404 (1) and Pembrolizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.